Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 27, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Annual Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
There are no material changes to financial performance reported in this filing. The document details an increase in share interests for specific individuals following the re-investment of dividends paid on July 12, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly reports on compliance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b) regarding director transactions.
Important Facts for Investors
- Dividend re-investment occurred at a price of GBP 12.97 per share.
- Transactions were notified on July 26, 2007, for the following individuals: Dr M M Slaoui (198 shares), Mr R M Bondy (256 shares), Mr M M Dunoyer (95 shares), Mr D Learmouth (17 shares), Dr D Pulman (146 shares), and Mr A P Witty (89 shares).
- The report was signed by Victoria Whyte as the Authorised Signatory on July 27, 2007.